Date: 2014-04-24
Type of information: R&D agreement
Compound: small-molecule TRPC4/5 inhibitors
Company: Boehringer Ingelheim (Germany) Hydra Biosciences (USA - MA)
Therapeutic area: CNS diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On April 24, 2014, Hydra Biosciences, a US company working in the field of Transient Receptor Potential (TRP) channel modulation, and Boehringer Ingelheim have announced that they have entered into a worldwide collaboration to research and develop small-molecule TRPC4/5 inhibitors for the treatment of central nervous system (CNS) diseases and disorders. Under the terms of the collaboration agreement, the companies will work together to identify and advance candidate inhibitors. Boehringer Ingelheim is responsible for the global development and commercialization of the inhibitors that come from the collaboration. Hydra will receive an upfront payment, additional research funding, and is eligible to receive milestone payments and tiered royalty payments on future product sales.
Financial terms:
Latest news:
